Accessibility Menu
Maze Therapeutics logo

Maze Therapeutics(NASDAQ) MAZE

Market Cap$1.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+67%
5 YearN/A
1 Year+83%
1 Month-1%
$26.54
-0.11%
-0.03Today
After hours$26.51-$0.03 (-0.13%)
Maze Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 26.532026-09-01
Maze Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.79%USD 30.422026-08-25
1 month-1.45%USD 26.922026-07-31
3 month+6.72%USD 24.862026-06-03
Year to date-35.96%USD 41.432025-12-31
1 year+83.09%USD 14.492025-08-29
Since inception+66.58%USD 15.952025-01-31

Maze Therapeutics Financials at a Glance

Market Cap

$1.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$20.00M

Net Income (TTM)

-$133.59M

EPS (TTM)

-$2.53

P/E Ratio

-10.49

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$26.54

Volume

326,661.016

Open

$26.32

Previous Close

$26.53

Daily Range

$25.81 - $26.66

52-Week Range

$14.16 - $53.65

Estimated Earnings Date

Nov 5, 2026

MAZE News

SellAlert-Green.png

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Robert IzquierdoJun 29, 2026
SellAlert-Red.png

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

Robert IzquierdoJun 5, 2026
SellAlert-Green.png

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Jonathan PoncianoMay 17, 2026
SellAlert-Purple.png

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

Sarah SidlowMay 7, 2026
SellAlert-Blue.png

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Robert IzquierdoApr 4, 2026
SellAlert-Red.png

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

Jonathan PoncianoMar 25, 2026
SellAlert-Purple.png

Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears

Adé HennisMar 21, 2026
SellAlert-Blue.png

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Adé HennisFeb 16, 2026
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Maze Therapeutics

Maze Therapeutics, Inc. makes pills for kidney and metabolic diseases. It uses human genetics to find new ways to treat patients. The company targets genetic triggers to stop illnesses.

Medicine for the Genetic Code

  • MZE829: Oral pill for kidney disease caused by a protein called apolipoprotein L1; currently the most advanced program in Phase 2 trials.
  • MZE782: Treatment candidate for phenylketonuria, which is a rare inherited metabolic disorder, and chronic kidney disease.
  • MZE001: Small molecule inhibitor for Pompe disease; licensed to an external partner for research and commercialization.
  • Compass Platform: Genetics-based technology that identifies specific risk factors to guide drug discovery and trial design.

Strategic Partnerships and Capital

  • Licensed MZE001 to Shionogi in March 2024 for an upfront payment of $150 million.
  • Launched a research collaboration with Neurocrine Biosciences in 2024 to study a specific genetic target.
  • Formed Broadwing Bio in 2020 with Alloy Therapeutics to develop antibody therapies for eye diseases.
  • Secured a senior secured term loan facility for up to $200 million from Hercules Capital in February 2026.

Targeted Treatment Science

Maze uses a process called variant functionalization to find disease-causing genetic changes. This strategy helps the company design precision medicines for specific groups of patients.

Funding the Path to Approval

  • Market cap reached $1.8 billion in the second quarter of 2026, up 227.2% year over year.
  • License revenue was $20 million for the six-month period ended June 30, 2026.
  • Net loss reached $68.9 million for the six-month period ended June 30, 2026.
  • Cash and marketable securities totaled $494.9 million as of June 30, 2026.
  • Price-to-earnings ratio was -9.8 in the second quarter of 2026.

Evolution of Genetic Medicine

Maze has moved from early research to testing multiple drug candidates in human clinical trials. It uses its genetics platform and drug industry partnerships to develop treatments for chronic conditions.

AI Generated • Aug 12, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

141

CEO

Jason V. Coloma, PhD, MBA

Website

www.mazetx.com

Headquarters

South San Francisco, CA 94080, US

MAZE Financials

Key Financial Metrics (TTM)

Gross Margin

95.28%

Operating Margin

-728.06%

Net Income Margin

-667.95%

Return on Equity

-34.94%

Return on Capital

-37.78%

Return on Assets

-25.13%

Earnings Yield

-9.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

55.55M

Volume

326.66K

Avg. Volume

548.31K

Financials (TTM)

Gross Profit

$19.06M

Operating Income

-$145.61M

EBITDA

-$130.28M

Operating Cash Flow

-$106.54M

Capital Expenditure

-$302.00K

Free Cash Flow

-$106.84M

Cash & ST Invst.

$411.09M

Total Debt

$60.42M

Maze Therapeutics Performance Analysis

Maze Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 167,500,000N/A
20252025-12-31USD 0N/A
Maze Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30-100.0%
Maze Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.63N/A
20232023-12-31USD -2.29-12.6%
20242024-12-31USD 0.08N/A
20252025-12-31USD -2.66N/A
Maze Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3014.3%
Q42025-12-31-31.8%
Q12026-03-3148.3%
Q22026-06-30-68.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$1.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.47M

N/A

Employees

141

N/A

Net Income

-$44.73M

-32.8%

EBITDA

-$43.80M

-32.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$411.09M

+55.4%

Total Debt

$60.42M

+141.6%

Accounts Receivable

$2.80M

N/A

Inventory

$0.00

N/A

Long Term Debt

$55.54M

+173.7%

Short Term Debt

$4.88M

+3.5%

Return on Assets

-25.13%

N/A

Return on Invested Capital

-28.63%

N/A

Free Cash Flow

-$15.16M

+50.2%

Operating Cash Flow

-$15.05M

+49.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NTLAIntellia Therapeutics, Inc.
$12.69-0.35%
WVEWave Life Sciences Ltd.
$4.97+1.43%
ARDXArdelyx, Inc.
$3.76-0.53%
ZYMEZymeworks Inc.
$29.67+0.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About MAZE

What is the current price of Maze Therapeutics?

Maze Therapeutics is trading at $26.53 per share.

What is the 52-week range for Maze Therapeutics?

Over the past 52 weeks, Maze Therapeutics has traded between $14.16 and $53.65.

How much debt does Maze Therapeutics have?

As of the most recent reporting period, Maze Therapeutics reported total debt of $60.42M.

How much cash does Maze Therapeutics have on hand?

Maze Therapeutics reported $202.64M in cash and cash equivalents in its most recent financial results.

What is Maze Therapeutics’s dividend yield?

Maze Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services